Answers are grounded in this paper and cite their sources.
RNA editing, a post-transcriptional process altering RNA sequences, is crucial in cancer progression. Adenosine-to-inosine (A-to-I) editing, mediated by ADAR enzymes, and cytosine-to-uridine (C-to-U) editing, by APOBEC proteins, diversify the transcriptome and proteome. Dysregulation of RNA editing significantly impacts gene expression, promoting tumorigenesis through alterations in amino acid sequences, transcript stability, and miRNA targeting. Conflicting research highlights the complexity of RNA editing’s role in cancer. While hyper-editing often correlates with editase overexpression and aggressive phenotypes, hypo-editing links to lower expression. Specific RNA editing events, rather than overall levels, offer more precise insights. ADAR1 primarily promotes oncogenesis, while ADAR2 generally acts as a tumor suppressor. ADAR3’s role remains unclear. RNA editing also influences noncoding RNAs, including miRNAs and lncRNAs, affecting their function and stability. A-to-I editing regulates miRNA biogenesis and mRNA-miRNA interactions, altering target gene selection and processing. LncRNAs, susceptible to A-to-I editing, undergo modifications that disrupt crucial molecular interactions, impacting their roles as miRNA sponges and regulators of gene expression. CircRNAs, through ADAR-mediated regulation, contribute to the complexity of RNA editing’s influence on cancer. This review underscores RNA editing’s multifaceted role in cancer, impacting key signaling pathways and immune surveillance. Understanding these mechanisms is vital for developing targeted therapies and improving cancer outcomes.
No takes yet. Share an insight, caveat, or question.
Sabit et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: